Deutsche Bank initiated coverage of Immatics (IMTX) with a Buy rating and $10 price target The firm likes the company’s setup to tackle cutaneous melanoma. Immatics’ TCR-based therapies have produced “mixed” clinical results in early- and mid-stage trials to date, which has the shares are trading at around cash levels, the analyst tells investors in a research note. However, Deutsche believes IMA203 may have a place in serving the unmet second-line cutaneous melanoma population, particularly if it can generate a 75% one-year overall survival rate from the pivotal Phase 3 SUPRAME trial data expected late 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMTX:
- Immatics: Promising Pipeline and Financial Stability Drive Buy Rating
- Immatics Reports Increased Q1 2025 Loss Amid Rising R&D Costs
- Immatics reports Q1 EPS (EUR 0.33) vs (EUR 0.03) last year
- Immatics: Strong Buy Rating Backed by Pipeline Progress and Financial Stability
- Immatics Reports Strong 2024 Financial Results and Progress